생체내 독성 시험 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 독성 시험별, 동물 모델별, 용도별, 지역별 및 부문별 예측(2026-2033년)

In Vivo Toxicology Market Summary

The global in vivo toxicology market size was valued at USD 5.3 billion in 2025 and is projected to grow from USD 5.7 billion in 2026 to USD 9.9 billion by 2033, at a CAGR of 8.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The market growth is driven by the increasing demand for in vivo toxicology industry in preclinical safety and toxicity assessment across pharmaceutical and biotechnology development.

The in vivo toxicology industry is witnessing significant growth, driven by increasing demand for preclinical safety assessment in pharmaceutical and biopharmaceutical drug development. Growing investment in drug discovery, expanding pipelines of novel therapeutics, and the need to evaluate toxicity and potential adverse effects before clinical trials are supporting market expansion. Continuous advancements in digital animal monitoring, sensor technologies, artificial intelligence, and machine learning are also improving the efficiency and effectiveness of in vivo toxicology studies, supporting market growth over the forecast period.

Global In Vivo Toxicology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global in vivo toxicology market report based on product, toxicology testing, animal model, application, and region.

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Instruments & Equipment
• Consumables
• Toxicology Testing Services
• Toxicology Testing Outlook (Revenue, USD Billion, 2021 - 2033)
• Acute Toxicity
• Repeated-Dose/Systemic Toxicity
• Reproductive & Developmental Toxicity
• Genotoxicity
• Carcinogenicity
• Immunotoxicity
• Other Specialized & Target-Organ Toxicity
• Animal Model Outlook (Revenue, USD Billion, 2021 - 2033)
• Rodents
• Non-Rodents Mammals
• Non-Mammalian Models
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharmaceuticals & Biotechnology
• Chemicals & Agrochemicals
• Food & Nutrition
• Medical Devices
• Other Applications
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Toxicology Testing Segment
    • 1.1.1.3. Animal Model Segment
    • 1.1.1.4. Application Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Adoption of Digital Technologies in Preclinical Animal Studies
    • 3.2.1.2. Growing Focus on Drug Safety and Early Toxicity Detection
    • 3.2.1.3. Increasing Adoption of Translational and Predictive Toxicology Approaches
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Growing Regulatory and Ethical Restrictions on Animal Testing
    • 3.2.2.2. High Cost and Time-Intensive Nature of In Vivo Toxicology Studies
  • 3.2.3. Market Opportunities Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape
    • 3.3.2.6. Environmental landscape

Chapter 4. Product Business Analysis

• 4.1. Segment Dashboard
• 4.2. In Vivo Toxicology Market: Product Movement Analysis
• 4.3. Instruments & Equipment
  • 4.3.1. Instruments & Equipment Market, 2021-2033 (USD Billion)
• 4.4. Consumables
  • 4.4.1. Consumables Market, 2021-2033 (USD Billion)
• 4.5. Toxicology Testing Services
  • 4.5.1. Toxicology Testing Services Market, 2021-2033 (USD Billion)

Chapter 5. Toxicology Testing Business Analysis

• 5.1. Segment Dashboard
• 5.2. In Vivo Toxicology Market: Toxicology Testing Movement Analysis
• 5.3. Acute Toxicity
  • 5.3.1. Acute Toxicity Market, 2021-2033 (USD Billion)
• 5.4. Repeated-Dose/Systemic Toxicity
  • 5.4.1. Repeated-Dose/Systemic Toxicity Market, 2021-2033 (USD Billion)
• 5.5. Reproductive & Developmental Toxicity
  • 5.5.1. Reproductive & Developmental Toxicity Market, 2021-2033 (USD Billion)
• 5.6. Genotoxicity
  • 5.6.1. Genotoxicity Market, 2021-2033 (USD Billion)
• 5.7. Carcinogenicity
  • 5.7.1. Carcinogenicity Market, 2021-2033 (USD Billion)
• 5.8. Immunotoxicity
  • 5.8.1. Immunotoxicity Market, 2021-2033 (USD Billion)
• 5.9. Other Specialized & Target-Organ Toxicity
  • 5.9.1. Other Specialized & Target-Organ Toxicity Market, 2021-2033 (USD Billion)

Chapter 6. Animal Model Business Analysis

• 6.1. Segment Dashboard
• 6.2. In Vivo Toxicology Market: Animal Model Movement Analysis
• 6.3. Rodents
  • 6.3.1. Rodents Market, 2021-2033 (USD Billion)
• 6.4. Non-Rodent Mammals
  • 6.4.1. Non-Rodent Mammals Market, 2021-2033 (USD Billion)
• 6.5. Non-Mammalian Models
  • 6.5.1. Non-Mammalian Models Market, 2021-2033 (USD Billion)

Chapter 7. Application Business Analysis

• 7.1. Segment Dashboard
• 7.2. In Vivo Toxicology Market: Application Analysis
• 7.3. Pharmaceuticals & Biotechnology
  • 7.3.1. Pharmaceuticals & Biotechnology Market, 2021-2033 (USD Billion)
• 7.4. Chemicals & Agrochemicals
  • 7.4.1. Chemicals & Agrochemicals Market, 2021-2033 (USD Billion)
• 7.5. Food & Nutrition
  • 7.5.1. Food & Nutrition Market, 2021-2033 (USD Billion)
• 7.6. Medical Devices
  • 7.6.1. Medical Devices Market, 2021-2033 (USD Billion)
• 7.7. Other Applications
  • 7.7.1. Other Applications Market, 2021-2033 (USD Billion)

Chapter 8. Regional Business Analysis

• 8.1. In Vivo Toxicology Market Share By Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. North America In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. U.S. In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Canada In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Mexico In Vivo Toxicology Market, 2021-2033 (USD Billion)
• 8.3. Europe
  • 8.3.1. Europe In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. UK In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Germany In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. France In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Italy In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Spain In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Denmark In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Sweden In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Norway In Vivo Toxicology Market, 2021-2033 (USD Billion)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Japan In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. China In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. India In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Australia In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Thailand In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. South Korea In Vivo Toxicology Market, 2021-2033 (USD Billion)
• 8.5. Latin America
  • 8.5.1. Latin America In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Brazil In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Argentina In Vivo Toxicology Market, 2021-2033 (USD Billion)
• 8.6. MEA
  • 8.6.1. MEA In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. South Africa In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Saudi Arabia In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. UAE In Vivo Toxicology Market, 2021-2033 (USD Billion)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Kuwait In Vivo Toxicology Market, 2021-2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share/ Position Analysis, 2025
• 9.3. Strategy Mapping
• 9.4. Company Profiles/Listing
  • 9.4.1. Charles River Laboratories
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Labcorp
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. WuXi AppTec
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Inotiv
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Pharmaron
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Altasciences
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Eurofins
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Evotec
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Aragen Life Sciences Ltd.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Jubilant Biosys Limited
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. The Jackson Laboratory
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Taconic Biosciences, Inc.
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives
  • 9.4.13. Bruker
    • 9.4.13.1. Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Strategic Initiatives
  • 9.4.14. Data Sciences International
    • 9.4.14.1. Overview
    • 9.4.14.2. Financial Performance
    • 9.4.14.3. Product Benchmarking
    • 9.4.14.4. Strategic Initiatives